Regeneron reported an insider share sale worth about $3.8 million, but gave no reason for it and reported no change to its business. The sale alone does not change the company's outlook.
The sale is personal share activity, and the report gives no reason for it. It reports no change to Regeneron's business or results, so this filing alone does not change the company's outlook.
Follow Regeneron Pharmaceuticals, Inc. (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for REGN